Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axsome’s pill has a safety advantage.

The partial government shutdown that left the Department of Homeland Security (DHS) unfunded for 75 days ended on Thursday. But the toll it has taken on the Transportation Security Administration (TSA) may still be felt for months to come, experts have warned.

Younger gamblers prefer electronic products to traditional ones but were not quick to embrace prediction markets when they debuted, if Nevada college students are any indication. These are among the more interesting findings of a study conducted by University of Nevada Las Vegas researchers at the International Gaming Institute.

The Hospitality Charitable Foundation has spent nearly 25 years helping underprivileged students in the Las Vegas valley pursue careers in hospitality — debt-free. The foundation provides full-ride scholarships to students attending UNLV, one of the nation's top hospitality management programs. The scholarships cover tuition, books, fees, and other expenses.

The agency’s decision marks the first approval of a drug with this specific mechanism of action for one of the most burdensome and clinically challenging symptoms of the disease.

That level of regeneration may be out of the question for humans right now, but at the University of Nevada, Las Vegas (UNLV), one lab team is researching the possibility of animal eye regeneration, and how that might impact human eyecare.

Unlike criminal warrants, ICE administrative warrants don’t require approval from an independent judge. ICE defends the practice, but legal experts say they can have errors and risk wrongful detention.

Providers of mental health support and families of patients fear the dire consequences that will come from changes to insurance coverage

Manoj Sharma, a professor of social and behavioral health and internal medicine, answers queries on understanding and coping with early-stage glaucoma.